Cyclophosphamide‐induced, nonhemorrhagic cystitis with abnormal bladder cells

Aptekar, Robert G.; Salisbury, Kent W.; Steinberg, Alfred D.; Myers, George H.

doi:10.1002/art.1780150509

Cited by 9 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the patients receiving cyclophosphamide, 15 % are known to develop haemorrhagic cystitis and the problem is more likely in patients who have received radiotherapy to the bladder region. The incidence of bladder carcinoma in patients who developed haemorrhagic cystitis while on cyclophosphamide is reported to be 7 ± 14 % (16,18,27) and so it is believed by some researchers that haemorrhagic cystitis is the harbinger of bladder carcinoma (1,31). Both the risk of haemorrhagic cystitis and that of bladder carcinoma seem to be higher in patients who have been exposed to both cyclophosphamide and to bladder irradiation.…”

Section: Discussionmentioning

confidence: 99%

Transitional Cell Carcinoma of the Urinary Bladder Following Exposure to Cyclophosphamide in Childhood

Agarwala¹,

Hemal²,

Seth³

et al. 2001

Eur J Pediatr Surg

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Transitional Cell Carcinoma of the Urinary Bladder Following Exposure to Cyclophosphamide in Childhood

Agarwala¹,

Hemal²,

Seth³

et al. 2001

Eur J Pediatr Surg

View full text Add to dashboard Cite

show abstract

“…2 URINARY BLADDER TOXICITY Jayalakshmamma and Pinkel 707 that an alkylating agent other than cyclo-are receiving or will receive radiotherapy to the phosphamide be considered in patients who pelvic region.…”

mentioning

confidence: 98%

Urinary-bladder toxicity following pelvic irradiation and simultaneous cyclophosphamide therapy

Jayalakshmamma

Pinkel

1976

Cancer

View full text Add to dashboard Cite

The frequency and severity of urinary-bladder toxicity were determined retrospectively in a large series of childhood cancer patients treated with either pelvic irradiation and simultaneous cyclophosphamide or cylclophosphamide with extrapelvic irradiation. Of 50 patients who received the first combination, 17 (34%) developed urinary-bladder toxicity. Eight of the 17 had transient hematuria and dysuria with complete clearing clinically after cessation of treatment; nine had chronic or intermittent hematuria which persisted after treatment was stopped and often resulted in demonstrable fibrosis and telangiectasia of the bladder. By contrast, of 60 children who received cyclophosphamide and radiotherapy outside the pelvic region, only five (8%) developed hematuria and in all instances it was transient. This comparative study demonstrates a significantly increased frequency and severity of urinary-bladder toxicity in cancer patients receiving pelvic irradiation with simultaneous cyclophosphamide.

show abstract

Cyclophosphoramide 50‐18‐0

2004

Sax's Dangerous Properties of Industrial Materials

View full text Add to dashboard Cite

Cyclophosphamide‐induced, nonhemorrhagic cystitis with abnormal bladder cells

Cited by 9 publications

References 5 publications

Transitional Cell Carcinoma of the Urinary Bladder Following Exposure to Cyclophosphamide in Childhood

Transitional Cell Carcinoma of the Urinary Bladder Following Exposure to Cyclophosphamide in Childhood

Urinary-bladder toxicity following pelvic irradiation and simultaneous cyclophosphamide therapy

Cyclophosphoramide 50‐18‐0

Contact Info

Product

Resources

About